Targeting Heparanase in Cancer: Inhibition by Synthetic, Chemically Modified, and Natural Compounds

• Main Authors: Chakrabhavi Dhananjaya Mohan, Swetha Hari, Habbanakuppe D. Preetham, Shobith Rangappa, Uri Barash, Neta Ilan, S. Chandra Nayak, Vijai K. Gupta, Basappa, Israel Vlodavsky, Kanchugarakoppal S. Rangappa
• Format: Article
• Language: English
• Published: Elsevier 2019-05-01
• Series: iScience
• Online Access: http://www.sciencedirect.com/science/article/pii/S2589004219301312

Heparanase is an endoglycosidase involved in remodeling the extracellular matrix and thereby in regulating multiple cellular processes and biological activities. It cleaves heparan sulfate (HS) side chains of HS proteoglycans into smaller fragments and hence regulates tissue morphogenesis, differentiation, and homeostasis. Heparanase is overexpressed in various carcinomas, sarcomas, and hematological malignancies, and its upregulation correlates with increased tumor size, tumor angiogenesis, enhanced metastasis, and poor prognosis. In contrast, knockdown or inhibition of heparanase markedly attenuates tumor progression, further underscoring the potential of anti-heparanase therapy. Heparanase inhibitors were employed to interfere with tumor progression in preclinical studies, and selected heparin mimetics are being examined in clinical trials. However, despite tremendous efforts, the discovery of heparanase inhibitors with high clinical benefit and minimal adverse effects remains a therapeutic challenge. This review discusses the key roles of heparanase in cancer progression focusing on the status of natural, chemically modified, and synthetic heparanase inhibitors in various types of malignancies. : Biological Sciences; Glycobiology; Molecular Biology; Cell Biology Subject Areas: Biological Sciences, Glycobiology, Molecular Biology, Cell Biology